Lipid droplets control mitogenic lipid mediator production in human cancer cells.


Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
10 2023
Historique:
received: 30 03 2023
revised: 29 07 2023
accepted: 08 08 2023
medline: 11 9 2023
pubmed: 17 8 2023
entrez: 16 8 2023
Statut: ppublish

Résumé

Polyunsaturated fatty acids (PUFAs) are structural components of membrane phospholipids and precursors of oxygenated lipid mediators with diverse functions, including the control of cell growth, inflammation and tumourigenesis. However, the molecular pathways that control the availability of PUFAs for lipid mediator production are not well understood. Here, we investigated the crosstalk of three pathways in the provision of PUFAs for lipid mediator production: (i) secreted group X phospholipase A We combined lipidomic and functional analyses in cancer cell line models to dissect the trafficking of PUFAs between membrane phospholipids and LDs and determine the role of these pathways in lipid mediator production, cancer cell proliferation and tumour growth in vivo. We demonstrate that lipid mediator production strongly depends on TAG turnover. GX sPLA This study shifts the paradigm of PLA

Identifiants

pubmed: 37586657
pii: S2212-8778(23)00125-4
doi: 10.1016/j.molmet.2023.101791
pmc: PMC10470291
pii:
doi:

Substances chimiques

Group X Phospholipases A2 EC 3.1.1.4
Lipase EC 3.1.1.3
Fatty Acids, Unsaturated 0
Phospholipids 0
Diacylglycerol O-Acyltransferase EC 2.3.1.20

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101791

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Eva Jarc Jovičić (EJ)

Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia; Jožef Stefan International Postgraduate School, Ljubljana, Slovenia.

Anja Pucer Janež (AP)

Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia; Jožef Stefan International Postgraduate School, Ljubljana, Slovenia.

Thomas O Eichmann (TO)

Institute of Molecular Biosciences, University of Graz, Graz, Austria; Center for Explorative Lipidomics, BioTechMed-Graz, Graz, Austria.

Špela Koren (Š)

Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia; Jožef Stefan International Postgraduate School, Ljubljana, Slovenia.

Vesna Brglez (V)

Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia; Jožef Stefan International Postgraduate School, Ljubljana, Slovenia.

Paul M Jordan (PM)

Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany.

Jana Gerstmeier (J)

Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany.

Duško Lainšček (D)

Department of Synthetic Biology and Immunology, National Institute of Chemistry, Ljubljana, Slovenia; EN-FIST, Centre of Excellence, Ljubljana, Slovenia.

Anja Golob-Urbanc (A)

Department of Synthetic Biology and Immunology, National Institute of Chemistry, Ljubljana, Slovenia.

Roman Jerala (R)

Department of Synthetic Biology and Immunology, National Institute of Chemistry, Ljubljana, Slovenia; EN-FIST, Centre of Excellence, Ljubljana, Slovenia.

Gérard Lambeau (G)

Université Côte d'Azur (UCA), Centre National de la Recherche Scientifique (CNRS), Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR7275, Valbonne Sophia Antipolis, France.

Oliver Werz (O)

Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany.

Robert Zimmermann (R)

Institute of Molecular Biosciences, University of Graz, Graz, Austria; BioTechMed-Graz, University of Graz, Graz, Austria.

Toni Petan (T)

Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Ljubljana, Slovenia. Electronic address: toni.petan@ijs.si.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH